Key points
- Thymosin beta-4 and TB-500 should not be considered synonymous.
- There are human Phase 2 studies for full-length Tβ4 in areas such as dry eye and venous ulcers.
- Claims of tissue repair for the TB-500 fragment are largely based on preclinical research.
- In July 2026, the FDA reviewed TB-500 for wound healing in a 503A compounding evaluation and reported finding no clinical use data in patients.
- The content, purity, and sterility of TB-500 products obtained from the internet should not be assumed to be identical to the Tβ4 products used in clinical trials.
What is thymosin beta-4?
Tβ4 is a naturally occurring peptide found in numerous cells and body fluids. Because of its binding to actin and its association with cell migration, tissue remodeling, and inflammatory response, it has long been investigated in the fields of wound healing and regenerative medicine.
What is TB-500?
The name TB-500 is frequently used in the online and performance-oriented market for synthetic fragments associated with the LKKTETQ region of Tβ4. However, the exact identity, length, and purity of products sold under the name “TB-500” can vary. Therefore, directly extrapolating human studies conducted with Tβ4 to TB-500 injections is not scientifically sound.
Why does the tissue repair mechanism attract interest?
In preclinical studies, Tβ4 has been associated with cell migration, keratinocyte and endothelial function, collagen remodeling, angiogenesis, and modulation of inflammation. These mechanisms have formed the basis for regenerative research in tissues such as tendon, muscle, skin, and the ocular surface.
Human studies for thymosin beta-4
One of the areas where full-length Tβ4 has been investigated in humans is dry eye disease. In Phase 2 randomized trials, positive results have been reported for some symptoms and corneal staining measurements with topical Tβ4 eye drops. In a double-blind Phase 2 trial conducted in venous stasis ulcers, the safety of topical Tβ4 was found to be acceptable, and a potential to accelerate wound healing was observed at certain doses.
The 2026 FDA evaluation for TB-500
In the FDA’s July 2026 Pharmacy Compounding Advisory Committee evaluation, the free base and acetate forms of TB-500 were evaluated for “wound healing” purposes. The FDA reported that the nominator did not provide clinical evidence for wound healing, and its own literature search found no published information where TB-500 was administered to patients for the treatment of any disease or condition. This finding should be evaluated separately from earlier topical clinical studies of full-length Tβ4.
Use in muscle and tendon injuries
Popular claims that TB-500 accelerates muscle, tendon, or ligament healing are largely based on mechanistic and preclinical data. This biology is of interest from a research perspective; however, human clinical studies that would establish the injection protocol, dose, site of administration, and long-term safety in sports injuries are not yet sufficient.
Why is the route of administration important?
The results of Tβ4 in topical ocular or wound studies cannot be directly applied to subcutaneous or IV TB-500 use. The route of administration alters systemic exposure, immunogenicity, product purity, and safety. There is no approved standard IV or subcutaneous treatment protocol for TB-500.
Our approach at our Bodrum clinic
In our thymosin beta-4/TB-500 evaluation, we first clarify which molecule and which route of administration are being discussed. For goals involving chronic wounds, tendon-ligament injuries, or tissue repair, diagnosis, circulation, load management, rehabilitation, and existing standard treatments are addressed first. If an investigational peptide is considered, the product source, route of administration, and measurable goals are evaluated without confusing data on full-length Tβ4 with data on the TB-500 fragment.
Frequently asked questions
Are there human studies for thymosin beta-4?
Yes. There are Phase 2 human studies, particularly in the areas of topical dry eye and chronic wounds. These data do not mean that TB-500 injections will produce the same effect.
Does TB-500 accelerate tendon healing?
The preclinical tissue repair biology is promising; however, there is not yet robust human clinical data regarding TB-500 injections in tendon or ligament injuries.
Is IV TB-500 standard?
No. There is no approved and standardized IV TB-500 treatment protocol.
Related Content
References
- Sosne G, et al. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015. PMID: 25826322.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: randomized placebo-controlled phase II trial. 2015. PMID: 26056426.
- Thymosin beta 4 and venous ulcers: clinical phase 2 data. PMID: 20536470.
- U.S. FDA. July 23, 2026 Pharmacy Compounding Advisory Committee: TB-500-related bulk drug substances for wound healing.
Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: September 10, 2026
Warning: This content is for general medical informational purposes; it does not replace personal diagnosis or treatment recommendations.
